SHYFT Analytics, a data and analytics cloud for life sciences, announced that in the last quarter, six biopharma companies have chosen to launch their new therapies using the SHYFT platform. The company’s solutions are designed to meet the needs of manufacturers developing and launching complex therapies.
SHYFT CEO Zack King notes that more than half of newly launched drugs fail to meet market expectations, and the success rate is even lower with rare disease and specialty therapies due to smaller patient populations and complicated delivery. “The SHYFT platform is designed to overcome these challenges and is becoming the technology for drug launches in life sciences,” King said.
Rare and specialty brands face unique challenges when launching new therapies, especially with regards to managing and making sense of complex data. The SHYFT platform integrates hundreds of data sources, including provider, payer, prescription, claims, and electronic medical records data into a cloud data platform. SHYFT’s customers use the products to collaborate and engage customers, identify and onboard patients, understand prescribing influences, and optimize treatment adherence and outcomes.
SHYFT Analytics, a McKesson Ventures portfolio company, is the leading analytics cloud platform for life sciences with products and solutions designed specifically for the pharmaceutical, biotech, and medical device industry.
Read the full article here.